COR Stock Forecast 2025-2026
Distance to COR Price Targets
COR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cencora (COR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on COR and similar high-potential opportunities.
Latest COR Stock Price Targets & Analyst Predictions
Based on our analysis of 28 Wall Street analysts, COR has a bullish consensus with a median price target of $280.00 (ranging from $242.00 to $308.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $271.39, the median forecast implies a 3.2% upside. This outlook is supported by 10 Buy, 7 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Stephanie Davis at Barclays, suggesting a 10.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COR Analyst Ratings
COR Price Target Range
Latest COR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $274.00 |
| Feb 6, 2025 | Evercore ISI Group | John Belton | Outperform | Maintains | $280.00 |
| Jan 29, 2025 | Wells Fargo | Eric Luebchow | Equal-Weight | Maintains | $251.00 |
| Jan 24, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $301.00 |
| Dec 13, 2024 | Wells Fargo | Eric Luebchow | Equal-Weight | Maintains | $237.00 |
| Nov 7, 2024 | UBS | Kevin Caliendo | Buy | Maintains | $285.00 |
| Nov 7, 2024 | Baird | David Rodgers | Outperform | Maintains | $292.00 |
| Nov 7, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $290.00 |
| Nov 7, 2024 | Evercore ISI Group | John Belton | Outperform | Maintains | $285.00 |
| Oct 8, 2024 | Evercore ISI Group | John Belton | Outperform | Maintains | $250.00 |
| Oct 7, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $275.00 |
| Sep 18, 2024 | B of A Securities | Michael Funk | Neutral | Downgrade | $245.00 |
| Sep 6, 2024 | Baird | David Rodgers | Outperform | Maintains | $283.00 |
| Aug 21, 2024 | JP Morgan | Lisa Gill | Overweight | Maintains | $287.00 |
| Aug 1, 2024 | Baird | David Rodgers | Outperform | Maintains | $287.00 |
| Aug 1, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $249.00 |
| Jul 9, 2024 | Baird | David Rodgers | Outperform | Maintains | $285.00 |
| Jun 27, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $275.00 |
| May 2, 2024 | Baird | David Rodgers | Outperform | Maintains | $277.00 |
| Apr 30, 2024 | Citigroup | Michael Rollins | Buy | Maintains | $280.00 |
Cencora Inc. (COR) Competitors
The following stocks are similar to Cencora based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cencora Inc. (COR) Financial Data
Cencora Inc. has a market capitalization of $52.57B with a P/E ratio of 38.4x. The company generates $303.19B in trailing twelve-month revenue with a 0.5% profit margin.
Revenue growth is +12.8% quarter-over-quarter, while maintaining an operating margin of +1.0% and return on equity of +198.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cencora Inc. (COR) Business Model
About Cencora Inc.
Healthcare distribution and services provider.
Cencora Inc. generates revenue by providing pharmaceutical sourcing and distribution services to healthcare providers such as hospitals, pharmacies, and clinics. The company integrates logistics, consulting, and innovative solutions to enhance pharmaceutical supply chain operations, thus improving the efficiency of product availability.
With a global reach and a network of distribution centers, Cencora Inc. partners with pharmaceutical manufacturers and healthcare providers to streamline operations, reduce costs, and enhance patient outcomes. The company is headquartered in Conshohocken, Pennsylvania, and emphasizes sustainability, innovation, and strategic collaborations in its operations.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
46,000
CEO
Dr. Robert P. Mauch Ph.D., PharmD
Country
United States
IPO Year
2023
Website
www.cencora.comCencora Inc. (COR) Latest News & Analysis
Cencora (COR) has strong growth potential, suggesting it may significantly outperform the market.
Cencora's strong growth potential suggests it may deliver higher returns, attracting investor interest and potentially boosting its stock price.
Consider using the GARP strategy for a profitable portfolio. Notable stocks include NVDA, COR, JBL, and KLAC for potential value and growth.
The GARP strategy suggests a balanced approach to investing in stocks like NVDA, COR, JBL, and KLAC, indicating potential for both value and growth, attracting investor interest.
Cencora raised its 2025 earnings outlook and its stock is approaching a buy point from a newly formed base.
A raised earnings outlook signals strong future performance, potentially boosting Cencora's stock value, while proximity to a buy point indicates a favorable entry opportunity for investors.
COR is experiencing growth in its U.S. Healthcare Solutions segment but faces significant competition in the market.
COR's growth in the U.S. Healthcare Solutions segment signals strong demand, but competition could pressure margins and market share, impacting future profitability and stock performance.
Cencora (COR) has reached a 52-week high, prompting investors to examine its fundamentals for potential future gains.
Cencora's 52-week high signals strong performance, prompting scrutiny of fundamentals to assess future growth potential and investment risks.
Zacks Style Scores, part of the Zacks Premium service, aids investors in identifying strong stocks across value, growth, and momentum strategies.
Zacks Style Scores simplify stock selection across investment strategies, potentially improving returns and enhancing portfolio performance for various investor types.
Frequently Asked Questions About COR Stock
What is Cencora Inc.'s (COR) stock forecast for 2025?
Based on our analysis of 28 Wall Street analysts, Cencora Inc. (COR) has a median price target of $280.00. The highest price target is $308.00 and the lowest is $242.00.
Is COR stock a good investment in 2025?
According to current analyst ratings, COR has 10 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $271.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COR stock?
Wall Street analysts predict COR stock could reach $280.00 in the next 12 months. This represents a 3.2% increase from the current price of $271.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cencora Inc.'s business model?
Cencora Inc. generates revenue by providing pharmaceutical sourcing and distribution services to healthcare providers such as hospitals, pharmacies, and clinics. The company integrates logistics, consulting, and innovative solutions to enhance pharmaceutical supply chain operations, thus improving the efficiency of product availability.
What is the highest forecasted price for COR Cencora Inc.?
The highest price target for COR is $308.00 from at , which represents a 13.5% increase from the current price of $271.39.
What is the lowest forecasted price for COR Cencora Inc.?
The lowest price target for COR is $242.00 from Stephanie Davis at Barclays, which represents a -10.8% decrease from the current price of $271.39.
What is the overall COR consensus from analysts for Cencora Inc.?
The overall analyst consensus for COR is bullish. Out of 28 Wall Street analysts, 10 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $280.00.
How accurate are COR stock price projections?
Stock price projections, including those for Cencora Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
